Neuroptix Corporation


Senior Management Team

Daniel R. Vlock, MD, Chief Executive Officer

Dr. Vlock brings extensive pharmaceutical industry and academic experience in pharmaceutical drug development. Dr. Vlock is founder and CEO of Alopexx Pharmaceuticals which is developing a fully human monoclonal antibody directed against S. aureus.  He has also held senior-level medical and research positions at GPC Biotech, Inc., Pharmacia Corporation, Ethicon Endo-Surgery (a subsidiary of Johnson & Johnson Company), and Boehringer Ingelheim Pharmaceuticals, Inc., where he was involved in the development of numerous oncology drugs, medical devices and drug-device combinations. While at Pharmacia he ran the Celebrex Oncology Group. That group ran 2 large international cancer prevention trials (over 3500 patients) and was also responsible for the successful approval of Celebrex for the treatment of Familial Adenomatous Polyposis, a life-threatening pre-cancerous condition. This was the first drug ever approved for cancer prevention. While at other companies he ran programs which successfully developed and introduced 2 monoclonal antibodies into clinical trials. Prior to moving to industry, Dr. Vlock was on the faculty at Harvard Medical School, University of Pittsburgh School of Medicine and Yale University School of Medicine where he led laboratory and clinical programs in tumor immunology.

Dr. Vlock received his A.B. from Cornell University and an M.D. from Baylor College of Medicine. He completed a research fellowship in clinical immunology at Baylor College of Medicine, an internship and medical residency at Temple University Hospital and a senior medical residency and fellowship in medical oncology at Yale New Haven Hospital.

Tom Trometer, Chief Financial Officer

With over 25 years of experience, and with a strong track record in CFO leadership positions, Tom is responsible for the financial management of Neuroptix’s operations. In this role he provides oversight for the financial management of the business, directs the corporate treasury function, establishes the protocols and standards for internal reporting, including Human Resources, and assists in building the business model and plan, shareholder communication, and risk management for the company. Prior to forming his own practice, he was VP Finance and CFO of CableSoft, and was instrumental in raising capital and selling the company to Motorola.  Before CableSoft, Tom was VP of Finance and Treasurer of Opta Food Ingredients, a public company, and was instrumental in raising over $40M in equity funds. He was also a manager in the Middle Market and Growing Companies Division of Price Waterhouse Coopers.  Tom is a CPA with a BS in accounting from Canisius College in Buffalo, NY.

Charles Kerbage, PhD, MBA, Director of Research and Development

Charles Kerbage has a strong record of scientific research that encompasses a multidisciplinary background. He possesses a rare combination of knowledge and technical skills in a number of disciplines. He has successfully conducted numerous studies and carried out pioneering work in optical waveguides at Bell Laboratories and Lucent Technologies. In addition, he developed devices for optical detection of cardiac arrhythmia as a postdoctoral fellow at Harvard University and constructed technologies for imaging ocular tissues that represent a quantum leap in biomedical applications as a research fellow at Wellman Center for Photomedicine at Massachusetts General Hospital. Prior to Cognoptix, Dr.Kerbage was a lead optical scientist at General Electric where he developed optical systems to detect infectious diseases at the point-of-care. Dr. Kerbage received his PhD in Applied Physics from the School of Engineering and Applied Sciences at Columbia University and an M.B.A. from the School of Management at Boston University. He was the recipient of the Robert Simon Memorial Prize for the most outstanding research with tremendous impact from Columbia University. Dr. Kerbage has authored and co-authored more than 50 peer-reviewed publications and holds several product related patents.

Anne Cameron, PhD, Director, Marketing and Clinical Strategy

Anne has 18 years experience in the pharmaceutical and diagnostics industry including research and development, marketing, regulatory and business development. At GE Healthcare, she led the Alzheimer’s disease PET imaging initiative, and was instrumental in business development deals with Roche and Eli Lilly.  Prior to GE, she held senior management positions at Roche. She has launched products within psychiatry and neurology. She has developed global strategies for product development in Alzheimer’s disease both for therapeutics and diagnostics. Anne has during her years working in psychiatry and neurology worked with a number of key opinion molders and advocacy groups and composed and directed more than 50 advisory board meetings. She has produced various publications within the field of CNS.